Cytisine, a low-cost, generic smoking cessation aid used in Eastern Europe since the 1960s, increased the chances of successfully quitting smoking by two times compared with a placebo, according to a new study published in the journal Addiction. times more effective than nicotine replacement therapy. The smoking cessation tools are reported to have a good safety profile, with no evidence of serious safety issues.
Cystine is a plant-based compound that may relieve smoking withdrawal symptoms. It was first synthesized in Bulgaria in 1964 under the name Tabex, and later spread to other countries in Eastern Europe and Asia, where it is still sold today. In 2017, Polish pharmaceutical company Aflofarm began selling it as a prescription drug, Desmoxan, and Canada approved it for sale as an over-the-counter natural health product, Cravv.
The study pooled results from eight randomized controlled trials comparing cystine to placebo, involving nearly 6,000 patients. The combined results showed that cystine more than tripled the chances of successfully quitting smoking compared with placebo.
The study also looked at two randomized controlled trials comparing cystine and nicotine replacement therapy, which showed that cystine and varenicline were more effective; and three trials comparing cystine and varenicline, which found that It shows that cystine has no obvious therapeutic effect.
"Our study provides further evidence that cystine is an effective and inexpensive smoking cessation drug," Omar de Santi, the study's lead author, said in a statement. "There is an urgent need for cost-effective smoking cessation drugs." reducing smoking could be very useful in low- and middle-income countries."
Currently, Cytisine is not licensed or sold in most countries outside of Central and Eastern Europe, making it unavailable in much of the world. According to National World, cystine tablets will be available in the UK by the end of January.